Working… Menu
Trial record 21 of 198 for:    Recruiting, Not yet recruiting, Available Studies | Neonatal respiratory distress syndrome

Efficacy and Safety Study of HLCM051(MultiStem®) for Pneumonic Acute Respiratory Distress Syndrome (ONE-BRIDGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03807804
Recruitment Status : Recruiting
First Posted : January 17, 2019
Last Update Posted : March 6, 2019
Information provided by (Responsible Party):
Healios K.K.

Brief Summary:
The primary object of this clinical study is to investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonitis.

Condition or disease Intervention/treatment Phase
Respiratory Distress Syndrome, Adult Biological: HLCM051 Phase 2

Detailed Description:

The objectives of this clinical study are as follows:

  1. Primary objective To investigate the efficacy of HLCM051 in patients with ARDS caused by pneumonia
  2. Secondary objective To confirm the safety of HLCM05 in patients with ARDS caused by pneumonia
  3. Exploratory objective To investigate changes of biomarkers in patients with ARDS caused by pneumonia

The number of patients enrolled is 30 (20 patient in the HLCM051 group and 10 patients in the standard therapy group)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Standard Therapy as a Controlled, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of HLCM051(MultiStem) in Patients With Acute Respiratory Distress Syndrome (ARDS) Caused by Pneumonitis
Actual Study Start Date : January 1, 2019
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : May 31, 2021

Arm Intervention/treatment
Experimental: HLCM051 group
  • Patients will receive the standard therapy
  • A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute
Biological: HLCM051
HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.

No Intervention: Standard treatment group
•Patients will receive the standard therapy

Primary Outcome Measures :
  1. Ventilator-free days (VFD) [ Time Frame: 28 days after administration of the investigational product ]
    VFD for 28 days after administration of the investigational product

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provision of informed consent by the patient or his/her legal representative in case the patient is incapable of giving consent
  2. Male or female aged 20 to 90 years at informed consent
  3. Patients with ARDS caused by pneumonia of those who were diagnosed as having ARDS according to the Berlin Definition
  4. Patients who are confirmed to have the following findings in the Berlin Definition within the same 24 hours 1)Positive end-expiratory pressure (PEEP) ≥5 cm H2O and PaO2/FiO2 (P/F) ratio ≤300 mmHg 2)Bilateral shadows in chest X-ray or CT (pleural effusion, atelectasis, and nodular shadow are denied) 3)Respiratory failure that cannot be explained by cardiac failure and fluid overload
  5. Patients who underwent chest high-resolution computed tomography (HRCT)
  6. Patients with HRCT score ≥211 according to the abbreviated HRCT scoring system
  7. Patients with APACHE II score <27 at the diagnosis of ARDS
  8. Patients who underwent artificial respiration with intubation
  9. Patients who can start receiving the investigational product within 72 hours (3 days) after the diagnosis of ARDS
  10. Patients whose condition is expected to be stable for at least 4 hours after initiating investigational product administration "Stable" means the condition where there is no need for significant sustained increase in FiO2 or PEEP and the supportive care for the cardiovascular system is not required (e.g. an increase in the dose of norepinephrine or epinephrine by ≥0.1 mcg/kg/min or an increase in the dose of inotropic agent or vasopressor by ≥20% besides norepinephrine and epinephrine for blood pressure control)
  11. Women who are neither pregnant, breastfeeding, planning to become pregnant during the study period. Women of childbearing potential must agree on the use of appropriate contraceptive methods under the guidance of investigators through the completion of the clinical study
  12. Male patients who have female partners of childbearing potential must agree on the use of appropriate contraceptive methods under the guidance of investigators through the completion of the clinical study

Exclusion Criteria:

  1. Patients without life expectancy of 48 hours
  2. Patients who are under artificial dialysis at screening
  3. Patients whose life expectancy is <6 months because of complications at screening
  4. Patients under ventilator at home due to chronic respiratory disease
  5. Patients for whom one week or longer has passed since the attachment of ventilator
  6. Patients with obvious honeycomb lung at screening consistent with pre-existing late-stage interstitial lung disease
  7. Patients with clinically evident findings consistent with diffuse alveolar hemorrhage
  8. Patients with chronic respiratory disease that requires continuous domiciliary oxygen therapy
  9. Patients with severe COPD (stage III or severe according to the GOLD Classification)
  10. Patients with chronic pulmonary hypertension (class III or IV according to the World Health Organization Classification of Functional Status of Patients With Pulmonary Hypertension)
  11. Patients with a history of lung lobectomy, single-lung pneumonectomy or pulmonary transplantation
  12. Patients who are appropriate to be treated with extracorporeal membrane oxygenation (ECMO) at screening
  13. Patients who were resuscitated after cardio-respiratory arrest
  14. Patients with a history of ST-segment elevation myocardial infarction within 6 months before informed consent
  15. Patients with mean arterial (blood) pressure (MAP) <60 mmHg despite treatment with one or more vasopressor or cardiotonic agent
  16. Patients with severe chronic liver disease (Child-Pugh >10)
  17. Patients with a history of transplantation with autologous or allogeneic, bone marrow or peripheral stem cells for other purposes than the treatment of hematological tumor
  18. Any history of malignancy within the last 2 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or hematologic malignancy treated with bone marrow or peripheral stem cell transplantation.
  19. Patients with history with human immunodeficiency virus (HIV) infection.
  20. Patients with a history of acute allergic reaction to the preparations derived from human tissues, bovine or swine materials, and those who refuse the use of biological products due to religious reasons
  21. Patients who underwent splenectomy in the past
  22. Patients in whom ARDS is not judged by the investigator to be the cause of the clinical and radiographic findings fulfilling the Berlin criteria
  23. Patients who received other investigational drugs or products within 30 days prior to informed consent
  24. Patients who are participating or planned to participate in other clinical studies (except for observational clinical researches that do not require intervention) during this clinical study
  25. Patients who are inappropriate to participate in this clinical study because of significant complications or psychiatric disorders as judged by the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03807804

Layout table for location contacts
Contact: Tetsuya Oe +81-3-5777-8250
Contact: Emi Shimizu +81-3-5777-8250

Layout table for location information
Hirosaki University Hospital Recruiting
Hirosaki, Aomori, Japan, 0368203
Saiseikai Kumamoto Hospital Recruiting
Kumamoto, Japan, 8614193
Sponsors and Collaborators
Healios K.K.
Layout table for investigator information
Principal Investigator: Kazuya Ichikado, M.D., Ph.D. Saiseikai Kumamoto Hospital
Principal Investigator: Satoru Hashimoto, M.D., Ph.D. University Hospital, Kyoto Prefectural University of Medicine

Layout table for additonal information
Responsible Party: Healios K.K. Identifier: NCT03807804     History of Changes
Other Study ID Numbers: B04-02
First Posted: January 17, 2019    Key Record Dates
Last Update Posted: March 6, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Distress Syndrome, Newborn
Respiratory Distress Syndrome, Adult
Respiratory Tract Diseases
Infant, Newborn, Diseases
Acute Lung Injury
Pathologic Processes
Lung Diseases
Respiration Disorders
Infant, Premature, Diseases
Lung Injury